OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.

Quarter-by-quarter ownership
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$2,850,770
-8.9%
171,915
+122.3%
0.07%
-27.3%
Q2 2023$3,128,013
+31.6%
77,348
+30.5%
0.10%
+35.6%
Q1 2023$2,376,968
-99.8%
59,276
+196.4%
0.07%
+170.4%
Q1 2015$1,242,000,000
+13.2%
20,000
-20.0%
0.03%
+42.1%
Q4 2014$1,097,000,00025,0000.02%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2015
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders